Aytu BioPharma Q4 revenue misses estimates

Aytu Biopharma

23/09/2025 21:15

Overview

Aytu BioPharma fiscal 2025 revenue up 2% to $66.4 mln, misses Q4 estimates

Net loss narrows to $13.6 mln from $15.8 mln in fiscal 2024

EXXUA launch in fourth calendar quarter of 2025 expected to drive future growth

Outlook

Aytu to launch EXXUA in fourth calendar quarter of 2025

Company expects EXXUA to enter $22 bln US MDD market

Aytu anticipates EXXUA to drive significant growth in fiscal 2026

Result Drivers

ADHD REVENUE DECLINE - ADHD Portfolio revenue decreased slightly due to fewer prescriptions, offset by improved brand economics through Aytu RxConnect

PEDIATRIC GROWTH - Pediatric Portfolio revenue grew, driven by a return-to-growth plan that increased unit sales by 49%

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$15.14 mln
$17.90 mln (3 Analysts)
Q4 Net Income
-$19.82 mln
Q4 Adjusted EBITDA
Miss
$2 mln
$2.76 mln (3 Analysts)
Q4 Gross Profit
$10.25 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Aytu Biopharma Inc is $9.00, about 72.3% above its September 22 closing price of $2.49

Press Release: ID:nACSvBp5ma

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)